If they really do have a cure for liver cancer, then there's no question that with the 3.15 billion shares listed as outstanding (probably closer to 4 billion now) that the company would be worth 10-15 billion mcap. That would translate into a share price of $ 2.50 - 3.75. So forget about a buck.
The question is, will they actually achieve such? If the science behind 485 is real and true, well, then it's only a matter of time until this thing rockets. There's no way a major drug company would not want to swipe this up and who knows what they'd pay.
If the science is murky well, it may just build slowly or stagnate. But I'm thinking that things will probably work out in its favor.
I don't think that there'll be any problem getting the patent issued. It'll just take some time. But getting a patent issued is not as important as getting the "drug" approved. Surely getting the patent issued would boost the stock even more, but when the "drug" gets approved, phew, this thing will do a Gleason (Bang, Zoom!!)
News 
Market Data 
Discover 
AI
